Skip to main content
Jordan Schecter, MD, Hematology, Raritan, NJ

JordanMarkSchecterMD

Hematology • Raritan, NJ

Hematologic Oncology

VP Cellular Therapy

Join to view full profile

Dr. Schecter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schecter's full profile

Already have an account?

  • Office

    920 US-202 S
    Raritan, NJ 08869
    Phone+1 908-927-3159

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2007
  • Brown University
    Brown UniversityInternship, Internal Medicine, 2004 - 2005
  • The Warren Alpert Medical School of Brown University
    The Warren Alpert Medical School of Brown UniversityClass of 2004

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2006 - 2025

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...
    Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...
    Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Authored Content

  • Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple MyelomaDecember 2021

Press Mentions

  • DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj) Shows 51 Percent Reduction in Risk of Progression to Active Multiple Myeloma for Patients with High-Risk Smoldering Multiple Myeloma
    DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj) Shows 51 Percent Reduction in Risk of Progression to Active Multiple Myeloma for Patients with High-Risk Smoldering Multiple MyelomaDecember 8th, 2024
  • Carvykti Lowering Risk of Death as Second-Line Myeloma Therapy: Trial
    Carvykti Lowering Risk of Death as Second-Line Myeloma Therapy: TrialOctober 1st, 2024
  • CARVYKTI® Is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients with Multiple Myeloma as Early as Second Line
    CARVYKTI® Is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients with Multiple Myeloma as Early as Second LineSeptember 27th, 2024
  • Join now to see all

Professional Memberships

Dr. Jordan Schecter, Dr. Jordan Schecter, MD, Dr. J Schecter, Dr. Jordan Mark Schecter